Study identifies high-risk groups
Favorites chosen by Cleveland Clinic Cancer Center staff
Will cancer vaccine boost immunotherapy’s efficacy?
When to change treatment strategy
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Durvalumab monotherapy appears safe and well-tolerated
Encouraging clinical efficacy with no rise in adverse events